Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Rac1 Levels Linked to Mechanics of Invadopodia Formation and Metastasis

By BiotechDaily International staff writers
Posted on 09 Jun 2014
Image: Electron micrograph shows a cancer cell (upper darker area) that has formed three invadopodia that are penetrating the adjacent extracellular matrix (lower lighter area) (Photo courtesy of Yeshiva University).
Image: Electron micrograph shows a cancer cell (upper darker area) that has formed three invadopodia that are penetrating the adjacent extracellular matrix (lower lighter area) (Photo courtesy of Yeshiva University).
Cancer researchers have linked increases and decreases in the level of Rac1 protein to the appearance and disappearance of invadopodia, amoeboid-like protrusions used by metastatic cancer cells to invade neighboring tissues.

Invadopodia release enzymes that degrade the extracellular matrix (ECM) and allow cellular movement while propelling the cancer cell into neighboring tissues.

Rac1, also known as Ras-related C3 botulinum toxin substrate 1, is a protein encoded by the RAC1 gene. This gene can produce a variety of alternatively spliced versions of the Rac1 protein, which appear to carry out different functions. Rac1 is thought to play a significant role in the development of various cancers, including melanoma and non-small-cell lung cancer. As a result, it is now considered a therapeutic target for these diseases. Rac1 is a small (approximately 21 kDa) signaling G-protein (more specifically a GTPase), and is a regulator of many cellular processes, including the cell cycle, cell-cell adhesion, motility (through the actin network), and of epithelial differentiation (proposed to be necessary for maintaining epidermal stem cells).

To study Rac1 involvement in invadopodia dynamics, investigators at Yeshiva University (New York, NY, USA) developed a genetically encoded, single-chain Rac1 fluorescence resonance energy (FRET) transfer biosensor technique that, combined with live-cell imaging, revealed exactly when and where Rac1 was activated inside cancer cells.

Results obtained by this methodology revealed that low levels of Rac1 were found during formation of invadopodia and while they were actively degrading the ECM. Elevated Rac1 levels coincided with disappearance of the invadopodia. These findings were confirmed by using siRNAs to silence the RAC1 gene. When the gene was inactivated, ECM degradation increased. Conversely, when Rac1 activity was enhanced - using light to activate a Rac1 protein analog - the invadopodia disappeared.

“We have known for some time that invadopodia are driven by protein filaments called actin,” said senior author Dr. Louis Hodgson, assistant professor of anatomy and structural biology at Yeshiva University. “But exactly what was regulating the actin in invadopodia was not clear. Rac1 levels in invadopodia of invasive tumor cells appear to surge and ebb at precisely timed intervals in order to maximize the cells’ invasive capabilities. So high levels of Rac1 induce the disappearance of ECM-degrading invadopodia, while low levels allow them to stay—which is the complete opposite of what Rac1 was thought to be doing in invadopodia.”

“Rac1 inhibitors have been developed,” said Dr. Hodgson, “but it would not be safe to use them indiscriminately. Rac1 is an important molecule in healthy cells, including immune cells. So we would need to find a way to shut off this signaling pathway specifically in cancer cells.”

Related Links:

Yeshiva University



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.